---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092535"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:49:11.211909+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics reports Q4 net loss $38.7M, cash $343M; vopimetostat pivotal study on track for 2026

## Summary
- Net loss $38.7M for Q4 2025 ($0.29/share) vs $30.8M for Q4 2024; FY2025 net loss $101.6M vs $130.3M.
- Cash, equivalents and marketable securities $343.1M as of Dec 31, 2025; runway into 2028.
- Collaboration revenue $62.4M for FY2025, including full recognition of remaining Gilead deferred revenue after collaboration truncation.
- Vopimetostat pivotal study in 2L MTAP-del pancreatic cancer to start in 2026; initial phase 1/2 combo data with RAS(ON) inhibitors expected in 2026.
- Signed clinical supply agreement with Erasca for vopimetostat + pan-RAS molecular glue ERAS-0015; CEO succeeded by Malte Peters in January 2026.

## SEC filing metadata
- accession: 0001193125-26-092535
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/0001193125-26-092535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/tngx-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092535
- JSON: https://secwatch.observer/filing/0001193125-26-092535.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092535.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.